Published in Gene Therapy Weekly, August 12th, 1996
The collaboration focuses on development of gene therapy products in the areas of cancer and pulmonary disease. Under the terms of the agreement, Advanced Therapies applies its proprietary Artificial Viral Envelope (AVE) technology to the delivery and targeting of GTI's proprietary gene therapy programs. GTI/Sandoz have the exclusive right to market the resulting products worldwide.
"The combination of GTI's gene therapy technology coupled with the drug delivery...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.